MSL
LAB icon

Mackay Shields LLC’s Standard BioTools LAB Stock Holding History

Mackay Shields LLC’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-302,378
Closed -$3.73M – 1457
2019
Q2 		$3.73M Buy
302,378
+185,378
+158% +$2.36M 0.03% 666
2019
Q1 		$1.55M Buy
+117,000
New +$1.23M 0.01% 821

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Mackay Shields LLC's LAB Position: Q3 2019 in Review

Mackay Shields LLC sold out of Standard BioTools (LAB) in Q3 2019, closing a stake of 302,378 shares — an estimated $3.73M sold.

Mackay Shields LLC first reported a position in LAB in Q1 2019 and held it in 2 quarters. The position peaked at $3.73M in Q2 2019. 125 funds tracked by Wall St. Rank hold LAB as of Q3 2019.

  • Mackay Shields LLC reported no remaining Standard BioTools position as of Q3 2019 after selling out during the quarter.
  • Mackay Shields LLC sold 302,378 Standard BioTools shares in Q3 2019, an estimated $3.73M.
  • Mackay Shields LLC first reported a position in Standard BioTools in Q1 2019 and held it in 2 quarters.
  • Mackay Shields LLC's Standard BioTools position peaked at $3.73M in Q2 2019.
  • 125 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2019.

Based on Mackay Shields LLC's 13F filing for Q3 2019, filed 1 Nov 2019.